Specific Therapeutic Benefits of Cannabidiol (CBD) Validated by FDA

CannabisNewsWire Editorial Coverage: In a landmark announcement, the U.S. Food and Drug Administration (FDA) recently approved a drug derived from pure cannabidiol (CBD), Epidiolex, to treat seizures associated with certain forms of severe epilepsy, setting the stage for huge changes in the world of cannabidiol (CBD).

  • FDA approval of a cannabis-based drug represents seismic political, legal and economic shifts
  • Approval likely will lead to more clinical research and further validation of CBD therapeutic efficacy
  • CBD market projected to explode to more than $2 billion in two years with 39 percent CAGR

What’s most transformative about this drug approval is that this is the first time the FDA — the governmental arbiter of safe and effective medicine in the United States — has approved any substance derived from the cannabis sativa plant and validated certain therapeutic benefits of cannabidiol. The FDA is, to some extent, endorsing what has been anecdotally accepted by the masses for millennia.

CBD, a non-psychoactive cannabinoid that can be extracted from the industrial hemp plant, is understandably generating worldwide interest from both the scientific and investment communities. A large part of CBD’s mass appeal is that it’s believed to aid with a broad range of wellness concerns. CBD is known to interact with the human endocannabinoid system, which is found throughout the body’s nervous system, organs, connective tissues, glands and immune system. Research indicates CBD may have the potential to treat a wide range of conditions such as anxiety, high blood pressure, skin issues and chronic pain. It’s being researched to treat Alzheimer’s, and one study even suggests CBD might be a useful addition when given with conventional antipsychotic medications in the treatment of schizophrenia.

Continued rigorous clinical research is being conducted to further confirm all the potential therapeutic benefits that may be found in this cannabinoid extract. In the meantime, the mass appeal of CBD remains unabated, and the market for CBD products continues to grow at an astounding rate. Committed to the legal hemp-derived CBD market, Marijuana Company of America, Inc. (OTC: MCOA) (MCOA Profile) provides consumers with pure, hemp plant-based CBD nutritional products through its global hempSMART™ brand and has initiated broad-ranging, innovative cultivation programs for legal, high-quality hemp. Others vying for position in the burgeoning CBD space include Isodiol International, Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F), CV Sciences, Inc. (OTC: CVSI), PotNetwork Holdings, Inc. (OTC: POTN) and Medical Marijuana, Inc. (OTC: MJNA).

The Boom Has Just Begun

Three years ago, in 2015, the hemp-derived CBD market racked up $90 million in sales. Last year that number reached $190 million in sales — and the boom has just begun. The Hemp Business Journal projects $2.1 billion in total CBD sales by 2020 and estimates that $450 million of that will come from hemp-based sources. The explosive demand projections are attributed to an increased public awareness of the wide-ranging potential health benefits of hemp CBD oil and advancements in cultivation, plus the convenience and reach of online retailing — all of which contribute to a global CBD oil market expected to grow at an eye-popping CAGR of 39.19 percent through 2021.

Hemp Focus

With an overarching focus on the cultivation, development and distribution of legal industrial hemp-derived products, Marijuana Company of America (OTC: MCOA) aims to capture an outsized share of growing worldwide demand. Pure hemp-based consumer nutritional products are at the core of this demand,  and the company has developed a portfolio of ancillary hemp-centric businesses to vertically integrate hemp production and sales. Cultivation of high-quality hemp from portfolio companies feeds MCOA’s proprietary CBD-based formulations, dovetailing to produce the finest quality nutritional supplements on the market.

The unique company vision emanates from Donald Steinberg, MCOA’s CEO. A cannabis industry pioneer, he founded the first cannabinoid-centric company to trade on a U.S. stock market. His vast knowledge and industry experience give MCOA unparalleled insights into the machinations of the CBD markets and the vision to capitalize on industry opportunities in a market projected to exceed $2 billion in the coming years. In keeping with this ambitious strategy, Steinberg and his partner, Charlie Larsen, formed Marijuana Company of America as well its sister company, Canadian-based Global Hemp Group, Inc. (OTC: GBHPF), which is focused on the legal cultivation and processing of industrial hemp. MCOA continues to build an impressive portfolio of synergistic companies across the hemp spectrum. From farm to finished products, MCOA’s socially conscious strategy is to capitalize at each profit point and establish a significant footprint at multiple inflection points across the entire hemp value chain.

Hemp-Based Nutritionals

MCOA has worked to create a recognized and respected hempSMART product line that contains levels of clinically researched ingredients designed to exceed consumer expectations and support the body’s natural endocannabinoid system. To serve health-conscious consumers, hempSMART includes an array of proprietary nutritional products.

  • hempSMART Brain is a patent-pending formulation designed for optimal brain function support.
  • hempSMART Drops offer the highest concentration and potency of full-spectrum bioavailable CBD.
  • hempSMART Pain Capsules contain a blend of premium CBD and botanical supplements.
  • hempSMART Pain Cream is a proprietary formulation for relief from muscle and joint pain.
  • hempSMART Full Spectrum Pet Drops is a unique nutritional supplement designed for furry family members.
  • hempSMART Face is a topical face moisturizer that combines CBD oil with ayurvedic herbs and botanicals.

MCOA’s hempSMART goes through an exacting CO2 extraction process to ensure the highest quality in the company’s natural wellness product line. By combining these pure industrial hemp-based cannabinoids with some of nature’s most effective wellness ingredients, MCOA’s hempSMART products are poised to deliver optimally formulated wellness products to health-conscious consumers.

In a forward-thinking plan to expand retail distribution and capitalize on impulse buys in high-traffic stores, MCOA took a 25 percent equity stake in BeniHemp-branded CBD products. BeniHemp health-focused products include topicals, tinctures and edibles packaged in one-day, two-day and thirty-day supplies widely distributed to convenience stores, smoke shops, gas stations and small retail outlets.

A Growing Portfolio

In addition to the hempSMART and BeniHemp consumer products lines, MCOA continues to strategically assemble synergistic portfolio companies. In a joint venture with sister company Global Hemp Group, MCOA launched a 125-acre industrial hemp cultivation project in northeast New Brunswick, Canada. The project targets the promotion of hemp farming while providing year-round jobs in crop and finished product processing.

Also in conjunction with Global Hemp Group, MCOA is developing Covered Bridge Acres, an innovative high-yielding CBD hemp cultivation project in Oregon. The project utilizes both traditional outdoor cultivation and what will ultimately become more than 19,000 square feet of indoor greenhouses, which are slated to eventually supply the raw oil needed for the hempSMART CBD product line.

MCOA also took a 15 percent equity stake in MoneyTrac Technology, Inc., a subsidiary of Global Payout, Inc. (OTC: GOHE). MCOA made this investment to help establish and market MoneyTrac Technology as an alternative banking solution for the cannabis industry.

Others Vying for Position

Isodiol International, Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) grows and harvests hemp on an industrial scale then processes it to extract the cannabidiol for distribution. The company commercializes pharmaceutical-grade cannabinoids, micro-encapsulations and nanotechnology for consumable and topical skin care products. Isodiol has announced plans to develop additional over-the-counter and pharmaceutical drugs, expand its phytoceutical portfolio and expand into Latin America, Asia and Europe.

CV Sciences, Inc. (OTCQB: CVSI) operates in two business segments. The company’s drug development division develops and commercializes novel therapeutics utilizing synthetic CBD. Its consumer product division manufactures, markets and sells plant-based CBD products to a range of market sectors. The company is also developing and pursuing FDA approval for drugs with specific indications utilizing cannabidiol as the active pharmaceutical ingredient.

Founded by MCOA CEO Donald Steinberg in 2009, Medical Marijuana, Inc. (OTC: MJNA) was the first U.S.-traded CBD company. The company develops, distributes and sells hemp oil that contains naturally occurring cannabinoids, including CBD. The company sells its hemp-derived CBD products through a variety of distribution subsidiaries. The company was among the first to bring hemp-based CBD oil products to market in the United States and the first to receive federal government import approvals in Mexico, Paraguay and Brazil.

PotNetwork Holdings, Inc. (OTC: POTN) is a publicly traded company that acts as a holding company for its subsidiaries, First Capital Venture Co.; Diamond CBD, Inc.; and Sunrise Auto Mall, Inc. Diamond CBD focuses on the research, development and multinational marketing of hemp extracts that contain a broad range of cannabinoids and natural hemp derivatives. Diamond CBD’s team consists of hemp industry professionals, chemists, doctors and scientists — all working together to produce CBD oils.

Seismic Shift

Modern science has begun to substantiate both the anecdotal history and the therapeutic efficacy of cannabidiol. The FDA’s recent approval of a cannabis-based drug represents a seismic shift and is further indication of the enormous curative potential that may be found in CBD. As more scientific validations ensue, the market for CBD products could easily exceed expectations, and well-positioned companies in the space could outperform the market.

For more information on Marijuana Company of America, visit Marijuana Company of America, Inc. (OTC: MCOA)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

$1 Trillion Global Health and Wellness Sector Presents Growing Opportunities for Cannabidiol Companies

CannabisNewsWire Editorial Coverage: Cannabidiol (CBD) products are reaching into the mainstream through a growing health and wellness sector, and savvy companies are looking to position themselves to make the most of this momentum.

  • The health and wellness market grown to over $1 trillion globally as of 2017
  • Positive shifting regulations globally is opening major international markets to CBD products, especially CBD infused food, beverages and natural health products
  • Larger fortune 500 level food and beverage companies are beginning to consolidate this major growth market via major investments and mergers and acquisitions.

In a groundbreaking move, Phivida Holdings, Inc. (CSE: VIDA) (OTCQX: PHVAF) (PHVAF Profile) has become the first CBD company to have their CBD food, beverage and natural health products cross over into major national mainstream grocery distribution in the United States. Isodiol International, Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) is also expanding CBD’s reach through a growing chain of vaping shops. And the potential for wellness beverages is demonstrated by Koios Beverage (CSE: KBEV) (OTC: SNOVF), with its expanding range of brain-boosting drinks. Within the cannabis market, The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) is providing organic, sustainable cannabis, a source of CBD that meets other consumer interests. And CV Sciences, Inc. (OTC: CVSI) is researching new CBD products and searching for ways to bring those products to market as the sector continues to grow in size and diversity.

Adding to Health and Wellness

The health and wellness sector is currently huge business. Conservative analysis places its value at over $1 trillion, while at least one commentator cites figures as high as $3.7 trillion. The willingness to make purchasing decisions based on better health and a longer life is no longer a niche interest. From gyms to health foods to counseling, consumers are spending a growing proportion of their income on creating healthier, happier lives.

Cannabidiol (CBD) products have become significant recent additions to the wellness market. Derived from cannabis plants, CBD is an active ingredient that has shown many potential health benefits without the intoxicating “high” provided by cannabis’ other main active ingredient, the THC found in marijuana. Research into CBD is still in its infancy, but that research has shown the ingredient’s potential to improve wellness in several ways. As legal changes make it easier to develop and produce CBD products, those products appear set to take an important place in the health and wellness market.

Reaching into the Grocery Market

One of the companies benefiting from this trend is Phivida Holdings, Inc. (CSE:VIDA) (OTC:PHVAF). Phivida (pronounced “fii-vee-daa”) is a producer of premium hemp oil extracts and capsules, the company provides health-conscious customers access to the benefits of CBD without unnatural chemicals. With a new C-suite management team in place consisting of former senior executives of Red Bull, Proctor & Gamble, Labatt’s and the former CEO of Seagram’s International, Phivida is now preparing to launch a CBD-infused beverage brand and has found a major partner to work with to ensure this strategic move is successful.

Phivida recently announced a groundbreaking exclusive national agreement with Acosta, Inc., a sales and marketing leader for the consumer-packaged goods industry in the United States, to distribute Phivida’s products, including the new beverage. Distributed through Acosta’s Natural Specialty Sales (NSS) division, Phivida’s drinks will be the first CBD hemp brand to cross over into the national mainstream distribution system in the states.

Natural specialty groceries are a significant market in North America, currently valued at USD $4.1 billion and growing. Obtaining a foothold in this market marks a historic milestone for CBD products, as well as a commercial coup for Phivida. NSS’s reach extends into 2,400 regional natural specialty grocery stores and the potential to expand into over 25,000 major national grocery stores across the U.S, including leading retailers such as Whole Foods, Sprouts, Walmart, and Kroger’s.

The major disruptive nature of the rapidly expanding cannabis and CBD-hemp markets have begun to draw attention from big players in the food and beverage industry as well. For example, Constellation Brands (NYSE: STZ) behind Corona beer and Svedka vodka, recently made a major investment in cannabis company Canopy Growth. And Southern Glazer’s, North America’s biggest wine and spirits distributor, has created a Canadian subsidiary to sell cannabis-infused products.

This trend is one that other major food, beverage and alcohol companies will almost certainly follow. As the market for CBD products grows, forward-thinking organizations will be looking for mergers and acquisition opportunities with CBD companies to gain exposure to this fast-growing market and protect their positions against disruption from the global cannabis sector.

Changing Regulations Drive Growth

The growth of the CBD sector is being driven by a global shift in the legal status of cannabis.

In the United States, regulated cannabis is now legal for both medical and recreational use in a number of states. On a national level, the Senate and House of Representatives are working to resolve differences between the two Congressional bodies’ versions of the 2018 Farm Bill, which include action to legalize industrial hemp. If the pro-hemp language remains in the final version of the bill, it would mark a significant shift in policy at the federal level, making it easier for businesses across the country to grow hemp and produce CBD products derived from it.

In Canada, the passing of Bill C-45 is set to make recreational cannabis legal across the country in October. The bill also includes rules for the production and sale of CBD-infused food and drink, creating a market for companies such as Phivida to sell new products as early as 2019.

Such moves are supported by the work of major global bodies. The World Health Organization (WHO) recently completed a report that found CBD is neither toxic nor addictive, making it safe for consumption. The report also highlighted CBD’s health benefits. The World Anti-Doping Agency (WADA) has removed CBD from its list of prohibited substances, allowing athletes to use it for treatment of pain and inflammations.

Making the most of this shift, Phivida is focusing on establishing an international presence. The deal with Acosta will provide distribution into a network of more than 27,000 U.S. retail outlets. In Canada, the company has created a joint venture with WeedMD to be the first to market with one of the first-ever federally legal cannabis beverage manufacturing facilities in the world — a major milestone. A deal with Namaste Technologies means Phivida products open the European Union and United Kingdom markets, while another deal with Asayake provides new opportunities for distribution in Japan. These partnerships have helped establish Phivida as the fastest-growing brand in CBD foods and beverages just as that market appears ready to take off.

Building a Business

Of course, CBD isn’t a magic product that will instantly give businesses success. Phivida’s achievements have been made possible by a skilled management team with experience in the beverages sector.

The company’s chief officers are all veterans of Red Bull’s North American operations, where they helped build the energy drink category from nothing to $300 million a year. CEO James Bailey worked as president of Red Bull Canada and held senior positions at Merrell Outdoors, Beneath Apparel, Adidas, Blue Goose and Salomon. Chief Marketing Officer Michael Cornwell is a former director of marketing at Red Bull Canada and was CMO at both Samsung NZ and Microsoft NZ. Chief Commercial Officer Doug Campbell was previously director of sales at Red Bull North America and director of national accounts at Stoli Group. The company’s advisers and directors also bring a powerful raft of experience to their roles, including time spent in senior management at Proctor and Gamble, in executive management at Labatt’s, and as CEO at Seagram’s International.

This powerful team is committed to ensuring Phivida operates with a tight capital structure. The company has more than $15.5 million CAD in cash and no debt. Just over 60 million shares have been distributed or are outstanding. With a fully diluted total of 71 million shares available, the company has ready access to approximately CAD $29 million in cash. With a strong leadership team and financial foundations, Phivida has achieved the first crossover of CBD beverages into major national mainstream retail distribution across the United States, as well as globally.

Surge of CBD

Regulatory change and consumer interest are also driving growth for a range of CBD and wellness businesses.

Isodiol International, Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) provides a wide range of CBD products. Through its KURE Corp. subsidiary, the company strongly promotes CBD in vaping products. KURE recently announced plans to expand its retail footprint by opening new premises and acquiring existing vaping stores.

 Koios Beverage (CSE: KBEV) (OTC: SNOVF) is a manufacturer and distributor of drinks and supplements designed to boost brain function, enhance health and improve productivity. The company recently announced the release of four new flavors of its brain-healthy drinks. Like Phidiva, Koios is turning beneficial supplements into beverages, making the drinks more appealing to a wide market.

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) produces cannabis tailored to the wider interests of health and well-being customers. Many of these consumers are deeply concerned with environmental issues, and the company’s organic, sustainably grown cannabis means that its products live up to these ethical standards.

 CV Sciences, Inc. (OTC: CVSI) is a CBD company with two distinct divisions. The pharmaceuticals part conducts research to develop new products, thereby expanding the possibilities of CBD. Meanwhile, the consumer products division focuses on getting those products to market.

The intersection of the CBD and wellness sectors is creating opportunities for businesses and consumers alike. As laws, attitudes and expectations continue to change around the world, these opportunities will only continue growing.

For more information about Phivida Holdings, please visit Phivida Holdings, Inc. (CSE:VIDA) (OTCQX:PHVAF)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Proposed Legal Changes Offer a Boost for Cannabidiol Companies in the United States

CannabisNewsWire Editorial Coverage: Recent growth in the market for cannabidiol (CBD) products has been strong and appears poised to continue.

  • CBD is an active ingredient derived from industrial hemp that does not contain the psychoactive or “high” effect of marijuana.
  • CBD is used in a wide range of products, from cosmetics to pet supplements.
  • The recent acceptance of a CBD-based medicine by U.S. authorities creates potential for legal change that could make the sale of CBD easier.
  • Attention in the mainstream press has created a measure of gravitas for CBD.

Marijuana Company of America Inc. (OTC: MCOA) (MCOA Profile) has produced a diverse range of CBD products to promote well-being. Cannabis company Canopy Growth Corp. (NYSE: CGC) has created a range of CBD oils for its customers while expanding its global reach. Aurora Cannabis, Inc. (OTCQX: ACBFF) provides pain relief through a range of cannabis strains and is set to expand its R&D potential through a takeover. Terra Tech Corp. (OTC: TRTC) provides equipment to cultivate cannabis and would benefit from a change in the legal landscape alongside its customers. PotNetwork Holding, Inc. (OTC: POTN) holds several subsidiary companies benefiting from cannabis and CBD products, thanks to the diversity of the sector.

U.S. Authorities Consider Legal Changes

For decades, federal rules have held back cannabinoid-derived medicines in the United States. Though the majority of states now allow medical marijuana and associated cannabinoid-derived products, national legislation is still grounded in the war on drugs. The cannabis and hemp plants are classified as a Schedule I drug, meaning that it is legally seen as both dangerous and without medical benefits. Even treatments using cannabidiol (CBD), an active ingredient found in hemp and cannabis that is nonpsychoactive, currently fall under this classification.

That may be about to change. Following the Food and Drug Administration’s (FDA) ground-breaking acceptance of prescription drug Epidiolex, the future of CBD products for medicinal use appears to be up in the air. Meanwhile, legislation from both sides of America’s political divide offers the possibility of bigger changes.

Tackling the Law

Progress on the legal status of CBD is being eagerly watched by companies such as Marijuana Company of America, Inc. (OTC: MCOA). With a focus on industrial hemp and hemp-derived cannabidiol products, MCOA doesn’t produce and sell medical or recreational marijuana. But because hemp products are derived from the same family of plants, they fall under the same stigmas associated with the plant.

Increasingly liberal legislation at the state level has allowed companies such as MCOA to thrive in the United States. But that evidence-based liberalization is in conflict with the federal government’s decades-long prohibition, which some within the current conservative government are looking to reinforce rather than relax.

Despite this, the FDA approved CBD-based Epidiolex in June. Epidiolex has been developed to counter the seizures brought on by two rare ailments. Its approval for sale as a prescription medicine doesn’t mean that similar medications will automatically be approved, but it does open the possibility. In light of the approval, repeated calls have been made for the FDA to look again at the scheduling of certain cannabinoids and the broader picture of cannabis-derived medicines.

At the same time, several pieces of legislation that could change CBD’s status are being considered by Congress. Some of those are actually being proposed by Republicans, making it appear less likely that they will be blocked by America’s more conservative party. It looks increasingly likely that rescheduling or other legislative changes may soon make it easier for companies to cultivate industrial hemp as well as produce and market CBD products.

When such change comes, companies with a wide array of products are likely to be the ones that will benefit most. With a range that already runs from pain treatment to therapies for pet care and memory enhancement, MCOA’s line of products is representative of how versatile the use of CBD can be. A loosening of restrictions would make it easier to both broaden this selection and make it available to a wider market.

CBD Goes Mainstream

The growth of companies such as MCOA is helped by increasing mainstream attention on CBD. Forbes has reported on research into the product by the World Health Organization. Esquire has profiled the rise and diverse uses of this ingredient. The Washington Post has explored the growing popularity of CBD among celebrities, consumers and wellness professionals.

Because CBD doesn’t get a user high, it might seem strange that the marijuana derivative is becoming one of the most popular hemp-derived products. But the wellness market is big business in America as consumers clamor for ways to improve their energy levels and reduce the low-key aches and pains of everyday life. CBD’s reputation for improving health is making it popular among people who want the reported medical benefits without having to deal with the high.

The result is a fast-growing market. Consumer sales of CBD amounted to $262.2 million in the United States in 2016, more than double what they had been only two years before. Based on the market’s ongoing growth, analysts have predicted that the market will hit the billion-dollar mark by 2021.

More than half of CBD consumers take the products every day with anxiety, anti-inflammation and joint pain being the top symptoms the products are designed to impact. Successful treatment of these conditions would likely create a large base of long-term consumers.

The Varied Uses of CBD

This large and growing consumer base is looking to CBD for potential impact on a wide range of wellness concerns. The ability of companies such as MCOA to provide a range of products aimed at these symptoms would allow those companies to tap into a broad share of the market. MCOA’s hempSMART™ products are a great example of how many uses a single company can find for CBD.

HempSMART Brain is a patent-pending nootropic product designed to support natural brain function, which fits with what many consumers expect from CBD because the product is focused on the mind. These innovative capsules can be taken to support alertness and concentration.

HempSMART Pain is designed to provide relief from pain associated with physical activity by combining CBD with botanical supplements. Their hempSMART Pain Cream is designed to provide temporary relief from and soothe sore, aching muscles and joints.

The company most recently launched a new cosmetic product, hempSMART Face, a CBD facial moisturizer that has been designed to refresh, replenish and restore skin cells on the face. And perhaps most surprising is the company’s offering of sublingual CBD tinctures, including hempSMART Full-Spectrum Drops and hempSMART Pet Drops, a bacon-flavored supplement formulated to provide cats and dogs with renewed energy as well as a tasty treat.

Such a diverse range of products could help a company such as MCOA attract the attention of CBD consumers. It might also allow consumers to use CBD in more areas of their lives, expanding the CBD market.

Companies Set to Benefit

It’s not just the variety of CBD products that bodes well for the industry — it’s also the range of companies. If the legal status of cannabis and cannabis-derived products changes, an entire sector is set to benefit.

Canopy Growth Corp. (NYSE: CGC), a leading player in retail cannabis, is using its research in the area to create CBD oils. By balancing the ratio of CBD and THC within its oils, Canopy Growth caters to differing wellness needs. Already a trusted player within the Canadian market, the company has acquired a subsidiary in the Kingdom of Lesotho and established another in Latin America. By looking to the wider world, the company is further expanding the global market for cannabis and CBD products.

One of the leading areas of interest for CBD is in pain relief. Aurora Cannabis, Inc. (OTCQX: ACBFF), one of the largest cannabis companies in the world, has established a strong position in this sector. The company has developed a large range of different strains of medical cannabis that can be used in developing new products as well as in retail. The Canadian Competition Bureau recently approved a takeover of MedReleaf Corp. (TSX: LEAF), a research-oriented company, by Aurora, leaving the company in a stronger position to make the most of the coming changes.

Rescheduling cannabis would benefit not just the companies selling cannabis and CBD products but also those supporting them. Terra Tech Corp. (OTC: TRTC) is a producer of environmentally friendly growing systems for cannabis growers. Its hydroponic systems use moving tables and recycled waste water to increase yields and reduce costs. As it becomes easier to grow and market cannabis, more growers may turn to Terra Tech for the equipment they need.

The maturity of the CBD and cannabis sector has also led to the emergence of several holding companies, including PotNetwork Holding, Inc. (OTC: POTN). This company’s subsidiaries include Diamond CBD, First Capital Venture and PotNetwork. Through these entities, PotNetwork benefits from growth across different parts of the industry, as well as supporting other companies in their expansion.

The market for CBD and other cannabis-derived products is already strong. With the prospect of legal rescheduling increasingly likely, these companies seem poised to benefit from changing attitudes in the United States and beyond.

For more information on Marijuana Company of America, visit Marijuana Company of America, Inc. (OTC: MCOA)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

CannabisNewsBreaks – Green Flower Opens Registration for August Introduction of ‘My Cannabis Career’ Summit

Ventura-based video platform company Green Flower yesterday announced that it has opened registration for the August 11, 2018, introduction of its ‘My Cannabis Career’ Summit. Per the update, the event is being produced to provide cannabis industry wannabe’s with an opportunity to hear directly from the best executives in the business. The summit is free for all interested participants on August 11 and available to ‘Premium’ subscribers thereafter. “These specialists have found their distinctive place in the Cannabis business,” Max Simon, CEO of Green Flower, stated in the news release. “Their unique experiences and challenges provide an abundant resource of information for those who are anxiously exploring their own paths in our industry. We specialize in sharing knowledge and believe that assisting future industry specialists through learning programs like this one is fundamental to strengthening the cannabis industry overall.”

To view the full press release, visit http://cnw.fm/sqR1F

About Green Flower

Established in 2014, Ventura-based Green Flower is the world’s largest video platform, maintaining 600+ affiliates to date. Dedicated to introducing only trusted cannabis knowledge, the platform boasts over 1,000+ hours of high-quality video content featuring 600+ top cannabis industry experts, doctors, scientists, entrepreneurs, and thought-leaders. Serving both consumers and professionals, Green Flower is the go-to platform for understanding every aspect of cannabis today. For more information, visit the company’s website at www.Green-Flower.com

More from CannabisNewsBreaks

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Hemp CBD Products Offer a Natural Alternative to Synthetic-Derived Medicines

CannabisNewsWire Editorial Coverage: The opioid crisis in North America has drawn attention to the urgent need for alternative medicines, and hemp CBD products offer a viable plant-based option.

  • An active ingredient in industrial hemp, Cannabidiol (CBD) can be extracted to be used in a number of different products such as topicals, tinctures, and capsules.
  • The World Health Organization (WHO) has found CBD to be nonpsychoactive, nonaddictive, and to have a positive effect on patients’ health.
  • Scientific studies have shown CBD to be effective in pain relief and, therefore, it may be a healthier alternative to addictive opioids.

Marijuana Company of America Inc. (OTC: MCOA) (MCOA Profile) is actively engaged in producing all-natural products containing CBD, including a recently released pain cream that can be applied topically to relieve discomfort. Cronos Group, Inc. (NASDAQ: CRON) has recently received a boost in funds and a license to produce cannabis products in Australia, allowing the company to grow its operations. Canopy Growth Corporation (NYSE: CGC), which produces oils containing CBD, is expanding into Lesotho and Colombia, exploring a global pain-relief market. Aurora Cannabis, Inc. (OTCQX: ACBFF), which already produces a wide range of medical marijuana strains, is in the process of acquiring an R&D company to strengthen its offerings. And Organigram Holdings, Inc. (OTCQB: OGRMF) produces medical strains that include a CBD option for patients and care providers eager to benefit from this ingredient.

The Opioid Epidemic

The United States is facing one of its greatest medical crises in decades — the opioid epidemic. During 2016 alone, 42,249 people died of opioid overdoses, 115 deaths every day. Despite the attention being turned onto this problem, most states are seeing further increases rather than declines in opioid abuse and its consequences. As the problem grows, physicians, emergency rooms and other healthcare providers are feeling pressure to find effective treatments for pain management, one of the largest causes of the growing problem.

Though illegal drugs such as heroin play their part, this crisis is fuelled by prescription drugs. The prescription painkiller problem began in the 1990s, when pharmaceutical companies persuaded healthcare providers that they could prescribe opioid painkillers without risk of addiction. This proved to be untrue, as large numbers of patients began misusing the drugs. Today, an estimated 21–29 percent of patients prescribed opioids misuse them, with 8–12 percent developing a disorder. And while misuse of legal drugs is a huge problem in its own right, it is also the gateway to illegal opioids. However, by the time the problem was recognized, the medical sector had become reliant on opioids. Pain relief is a critical part of modern medicine, which helps patients manage chronic conditions as well as cope with recovery from shorter-term illnesses, accidents and operations. Simply abandoning opioids was not an option.

An Alternative to Opioids

One option gaining increased attention may be the use of all-natural cannabidiol (CBD) products, as a plant-derived option to the use of synthetic prescription painkillers. These products do not contain THC, the ingredient that gets cannabis users high, and so can be used to provide relief without impairing a user’s normal mental activities. Products containing CBD, which have recently been developed by companies such as Marijuana Company of America (MCOA Profile), may offer a viable alternative to synthetic medicines.

CBD applications and uses have benefitted from changes surrounding that industry. Licenses  to grow industrial hemp have allowed companies to combine agriculture, R&D and product development with those seeking medical uses for hemp. MCOA’s recently established cultivation in Oregon is a prime example of this work, with researchers developing better growing techniques and improved plant strains that will allow them to extract higher yields of CBD oil.

A Healthier Option?

Scientific research into the effectiveness of CBD supports its potential in pain relief. A review of recent studies found that it was generally effective in helping patients manage their pain. Not only can it provide a viable alternative to opioid painkillers.

The advantage of CBD over opioids appear to be that it may provide a safer, healthier treatment option. CBD appears to be far less physically and mentally addictive than many prescribed pain medications. Patients can use it without experiencing the high risks of addiction that accompany many prescription painkillers.

The World Health Organization released a scientific research report conducted on CBD, which found the compound to be nonpsychoactive and nonaddictive; the report also noted that it has multiple health benefits. CBD oils provide patients with access to the relief that medical marijuana would bring but without many of the side effects.

Applied Medicine

By providing alternatives for relief, companies working with CBD are providing a pathway out of the opioid epidemic. One example of a CBD pain-management product is MCOA’s recently released hempSMART Pain Cream.

HempSMART Pain Cream is a topical treatment developed to reduce discomfort, support joint mobility, and relax muscles. Each bottle contains 300mg of full-spectrum CBD derived from industrial hemp, combined with other natural plant-based extracts. The cream contains the company’s own formulation of Ayurvedic herbs along with menthol, cayenne pepper extract, rosemary oil, aloe gel, white willow bark, arnica, wintergreen extract and tea tree oil. Together, these ingredients appear to provide an immediate cooling and soothing sensation, while the CBD helps to ease discomfort.

“We will continue to expand our health and wellness lines in 2018 to include more products,” said MCOA CEO Donald Steinberg. “Pain Cream has been enthusiastically received by our affiliates and customers.”

Pain Cream is just one of many hempSMART products already developed by MCOA. As more is learned about the potential uses of CBD in wellness products, the company will likely develop new products and treatments. From hempSMART Brain, a brain-enhancing formulation, to hempSMART Face, a CBD-infused cosmetic, the company is finding new ways to deliver the benefits of this chemical compound.

Cannabis Companies Explore Potential of CBD

Meanwhile, patients looking for pain relief have the chance to move away from prescription drugs and into treatments without the same risks of addiction. A number of other companies are also exploring the potential of CBD treatments.

One of the most prominent is Cronos Group, Inc. (NASDAQ: CRON), the first Nasdaq-traded company purely focused on cannabis. Though based in North America, the company has recently started branching out, obtaining a manufacturing license to produce products based on medical cannabis in Australia. Boosted by funds raised through a recent public offering, the company is set to become a global player in the field of cannabis-derived treatments, including pain medication.

Canopy Growth Corporation (NYSE: CGC) is also looking to bring cannabis and CBD treatments to a wider market. Having previously acquired a cannabis company in Lesotho, giving it access to the African market, the company is now expanding into Latin America through the acquisition of a Colombian company. Canopy Growth produces oils with varying levels of CBD to meet the varying needs of customers.

One of the world’s largest cannabis companies, Aurora Cannabis, Inc. (OTCQX: ACBFF) is heavily involved in pain relief through its wide selection of medical cannabis strains. The company recently took a step toward improving its research into cannabis-derived medicine, thanks to the Canadian Competition Bureau’s approval of a proposed takeover of MedReleaf. By acquiring another R&D-driven cannabis company, Aurora hopes to expand its own research into CBD-based medicines.

Medical cannabis company Organigram Holdings, Inc. (OTCQB: OGRMF) has produced a range of different strains, including CBD-rich options. It has recently been licensed to expand its production facilities, allowing the company to better meet the needs of a growing market.

With companies developing hemp-derived, CBD-based wellness products, a new alternative to synthetic opioid-based medications is emerging. CBD-based options may also provide access to the benefits of medical cannabis without that product’s mind-altering properties and other worrisome side effects.

For more information on Marijuana Company of America, visit Marijuana Company of America, Inc. (OTC: MCOA)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Cannabidiol Market Anticipates Growth as Regulatory Change Looms in U.S.

CannabisNewsWire Editorial Coverage: Restrictions in the United States on cannabidiol (CBD), an active ingredient in cannabis, appear likely to loosen over the next few months, creating opportunities for CBD production and distribution companies.

  • CBD is an active ingredient with medical benefits but no “high”, or pyshcoactive effects.
  • The Food and Drug Administration (FDA) has approved a CBD-based medicine for the first time.
  • Companies are cultivating hemp to develop high yielding CBD plants.

Marijuana Company of America, Inc. (OTC: MCOA) (MCOA Profile) is cultivating industrial hemp for CBD  propagation at sites in the United States and Canada while continuting to develop and manfuacture CBD-based products for its hempSMART™ brand. Cronos Group, Inc. (NASDAQ: CRON) is expanding its global reach for cannabis products through deals covering the United States, Canada, Australia and Poland, as this sector of the economy goes global. CV Sciences, Inc. (OTC: CVSI) is providing a clean bill of health for its CBD wellness products. Terra Tech Corp. (OTC: TRTC) is providing advanced hydroponic growing systems that increase crop yields and reduce costs for CBD-oriented companies. Manufacturer Liberty Health Sciences (OTC: LHSIF) produces cannabis in facilities recently certified as meeting high standards for manufacturing.

FDA Leads the Way to Reclassify Cannabidiol

The market for cannabis and hemp products has seen a low-key but potentially huge step forward in recent weeks. For the first time, the FDA has approved a medicine that uses cannabidiol (CBD) as its active ingredient. CBD is a compound that can be found in the hemp and cannabis plants, but unlike tetrahydrocannabinol (THC) it does not get users high.

Repeated studies have demonstrated the beneficial effects of cannabinoids. As a result, cannabis products have been approved for medical use in many states, but this is the first time that a cannabinoid-based CBD product has been approved at the federal level. This approval represents a softening of the federal government’s attitude. CBD was previously classified as a Schedule I drug by the Drug Enforcement Agency, but this body is now expected to change its stance within the next three months, allowing the possibility to manufacture products that would currently be banned on the national level. This possibility represents a huge moment for the CBD industry.

Better Plants for Better Health

One of the companies likely to benefit from this change is the Marijuana Company of America, Inc. (OTC: MCOA). The company is focused on the cultivation of industrial hemp and the manufacturing of hemp-derived CBD products, and is expanding its operations to better serve its growing market.

The most recent addition to the company’s operations is an industrial hemp cultivation site in Scio, Oregon. Created in collaboration with Global Hemp Group (GHG), this is a 109-acre site in the Willamette Valley. With its rich soil and pre-existing irrigation infrastructure, the valley provides an ideal location for an agricultural project that has already been home to cannabis cultivation in the past.

The Scio facility uses a mixture of cultivation practices. It has 19,000 square feet of greenhouse growing space under construction alongside fields for outdoor crops. This will allow the company to produce a steady supply of hemp all year, with high-yield plants ensuring a significant volume of output.

One of the main aims of the team working at Scio is to encourage plant strains that have a particularly high yield of CBD. Careful data collection and analysis are being used to assess the quality of plants and the effectiveness of techniques used to grow them. The expected change in the legal status of CBD in the United States will make it easier for MCOA to conduct research and cultivate CBD rich industrial hemp like at the Scio site, and for patients to have access to the products that come from it.

Working with Government to Improve Agriculture

MCOA and GHG are also collaborating on a similar project in New Brunswick, Canada, on a much larger scale. For this project, the two companies are working with the New Brunswick Department of Aquaculture, Agriculture and Fisheries (DAAF) to explore better approaches to growing hemp.

With markets for hemp and CBD reaching greater maturity, the DAAF has shown its faith in the future by awarding a grant of $10,750 to the joint MCOA and GHG venture in the region. These funds will be used on test projects for the current crop season, which will allow the companies to improve their cultivation techniques.

These government-funded tests are focused on three areas, two of which are looking at soil conditions to identify the best levels of nitrogen fertilizer for crops and whether soil acidity can be effectively adjusted using local supplies of slag lime. The third area of study is the European corn borer, a moth that damages crops and that has been a pest to farmers in the region. Damage from borers was found on hemp stalks last year, so the companies will be looking at the impact this damage could have on cultivation.

The latest technology is being used to ensure the success of these tests. A drone company has been employed to provide overviews of growth across hemp fields because the height of the stalks and density of cultivation makes assessment by other means difficult. With agricultural experiments underway in both Canada and the United States, MCOA has multiple opportunities to cultivate better CBD crops.

In New Brunswick, the two companies have created what they refer to as the Hemp Agro-Industrial Zone (HAIZ), where they are carrying out trials of hemp cultivation targeted at developing the industry in the province. By exploring cultivation techniques, ensuring a market for the product and providing consistent jobs for local farm workers, they aim to create a green-industry cluster specializing in hemp.

Creating Wellness

MCOA isn’t just a cultivation company. It is manufacturing its hemp crops into a wide range of products formulated to improve the well-being of customers.

Much of this work is carried out through hempSMART, the company’s most prominent consumer brand. HempSMART creates CBD-based wellness products and provides consumers with education about the potential benefits CBD may provide. Many consumers don’t understand the difference between CBD and THC products. Through hempSMART, MCOA is raising awareness while reaching out to a growing market.

The most recent release from hempSMART is the relaunch of its hempSMART Brain product. This version doubles the dose of CBD from the original, combining CBD oil with a blend of natural plant-based ingredients. Designed to maintain mental clarity, alertness, focus and concentration, as well as promote relaxation, restorative sleep, and the repair and regeneration of brain cells, hempSMART Brain is a flagship product that demonstrates MCOA’s wellness agenda. With the prospect of a change in the CBD compound’s legal status in the United States, companies such as MCOA will have more opportunities to develop and sell these types of products, spreading CBD-based wellness.

Growing Companies Profit from Changing Regulations

A range of companies in the cannabinoid sector will be in a position to profit from this change. Cronos Group, Inc. (NASDAQ: CRON) is demonstrating the global potential of cannabinoid products. The North American company already has a cross-border deal that allows it to make use of advances in both Canada and the United States. In addition, Cronos was recently granted a manufacturing license to produce cannabis-based products in Australia, and a new Polish distribution agreement will give the company a foothold in the European market.

CV Sciences, Inc. (OTC: CVSI) is firmly focused on the CBD sector. The company has two parts: a drug development division exploring novel CBD-based treatments and a consumer product division that manufactures, markets and sells the resulting products.

Some companies are focused on providing support and equipment for CBD cultivation. Terra Tech Corporation (OTC: TRTC) has created a hydroponic growing system that uses moving tables to increase yields by up to 30 percent while reducing costs by up to half. Its energy efficiency and recycling of waste water means that the company’s systems live up to the expectations of green-minded consumers.

Liberty Health Sciences (OTC: LHSIF) works in the medical cannabis market. As it acquires and operates U.S.-based cannabis companies, its aim is to produce safe, high-quality cannabis for patients. It has recently received Good Manufacturing Practice certification for its high standards of safety, consistency and quality.

Given the growing number of players in the cannabis market, a shift in the classification of CBD on a federal level could have a tremendous impact. For companies already focusing on CBD products, a huge opportunity for growth in the United States may be on the horizon.

For more information on Marijuana Company of America, visit Marijuana Company of America, Inc. (OTC: MCOA)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Farm Bill Legislation May Springboard Federal Hemp Acceptance

CannabisNewsWire Editorial Coverage: The United States House passed the 2018 Farm Bill, which will redefine subsidies to farmers, nutritional welfare recipients, conservationists and others. Tucked into this bill of more than 1,000 pages is hemp legalization legislation supported by Senate Majority Leader Mitch McConnell. Demand – and thus farming revenue – for tobacco is waning, and McConnell says hemp farming could help bolster farming communities in his home state of Kentucky and across the country. Currently listed as a controlled substance under federal law, the new bill will declassify hemp as a schedule 1 drug and label it as a viable agricultural commodity. Through its hempSMART™ subsidiary, Marijuana Company of America, Inc. (OTC: MCOA) (MCOA Profile) is one example of a few companies currently providing consumers hemp plant-based products under the rubric of existing laws, and the company has undertaken broad-based legal hemp cultivation programs. Other companies that could feel the ripples of change in the space are Isodiol International, Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F), CV Sciences, Inc. (OTC: CVSI), Medical Marijuana, Inc. (OTC: MJNA), and Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) (LXRP Profile).

Hemp’s History

Archaeological evidence reveals that for over 10,000 years hemp has been used by humans for pottery, shoes, ropes, clothing, food, medicine, and a wide array of other applications. Since early populations ingested hemp seeds, it stands to reason they also discovered the medicinal properties found in the plant. Ancient Asia, Egypt, India, Greece and the Islamic world all have rich histories relating to medicinal cannabis. In the 19th century, cannabinoids gained popularity for therapeutic use in Western medicine, but regulatory efforts imposed strictures during the 20th Century, eventually leading to a ban on its use in the U.S. under federal drug controls because of hemp’s relation to its more drug-user-friendly cannabis counterpart, marijuana. But, in recent years, society has turned to modern science to substantiate anecdotal claims about the therapeutic efficacy of non-psychoactive cannabidiol (CBD) found in the hemp plant.

“I know there are farming communities all over the country who are interested in this,” McConnell told the Senate Agriculture Committee amid debate over his bill. “Mine are particularly interested in it, and the reason for that is — as all of you know — our No. 1 cash crop used to be something that’s really not good for you: tobacco. And that has declined significantly, as it should, given the public health concerns.”

The federal government has exhibited schizophrenic regulatory tendencies toward hemp since the passage of the Marijuana Tax Act of 1937 that quashed hemp production with exorbitant excise taxes.  Reversing course during WWII, the government urged farmers to grow hemp for fiber and also waived taxes, and over 400,000 acres of hemp were cultivated between 1942 and 1945. After the war, hemp again had persona non grata status. Congress then passed the Controlled Substances Act in 1970, prohibiting the use of all cannabis for any purpose whatsoever and effectively terminating all industrial hemp production. Hemp extracts, however, are considered legal because they contain less than 0.3 percent THC, but the cultivation of hemp remains federally verboten. Now, the advancement of the Farm Bill signals a revived federal interest in the industrial hemp industry.

Hemp Pioneers

Led by hemp industry pioneers, Marijuana Company of America, Inc. (OTC: MCOA) has spearheaded efforts and staked claims on multiple legal hemp cultivation projects. The company’s innovative strategy is to vertically integrate hemp production and sales – from seed to shelf. Cultivation of quality hemp will feed MCOA’s innovative CBD-based formulations, which use the highest-quality hemp to produce what could be the finest-quality botanical supplements on the market. The hempSMART™ product line contains tested levels of clinically researched ingredients to meet consumer needs that support the body’s natural endocannabinoid system.

From seed to shelf, MCOA has built its business model around industrial hemp-based CBD products. Hemp has a myriad of uses beyond CBD therapeutics – as a food, a natural fiber, and even as a commodity in the building materials sectors. No part of the plant goes unused, and MCOA’s overarching strategy is to capitalize at each profit point – from farm to finished products. MCOA appears to be establishing a commanding presence at multiple inflection points across the entire hemp value chain.

hempSMART™, Inc.

Expanding on ancestral wisdom, MCOA has combined the most effective ingredients in wellness technologies with pure plant-derived industrial hemp-based cannabinoids to create optimally formulated wellness products for health-conscious consumers.

hempSMART™ offers a number of different products within a wide range of delivery systems, such as its capsule-based formulations hempSMART™ Brain, a patent-pending nootropic product designed to support natural brain function; and hempSMART™ Pain, which is formulated with a blend of premium full-spectrum CBD and botanical supplements designed for pain associated with physical activity.

The company also offers sublingual CBD tinctures to customers including hempSMART™ Full-Spectrum Drops and their natural pet supplement hempSMART™ Pet Drops with advanced bioavailability.

hempSMART™ has also expanded upon its established line of products by offering topical products such as hempSMART™ Pain Cream, which is designed to provide temporary relief and soothe sore, aching muscles and joints. The company also launched a new cosmetic product, hempSMART™ Face, a CBD facial moisturizer that has been designed to refresh, replenish and restore skin cells on the face.

MCOA’s hempSMART™ CBD consumer products are sold at www.hempsmart.com.

Hemp Cultivation

In what appears to be a vertically integrated business strategy, MCOA entered into a joint venture with Global Hemp Group Inc. (OTC: GBHPF) to launch multiple industrial hemp cultivation projects in the legal marijuana states of the U.S. and in Canada. The first is a 125-acre industrial hemp cultivation project in northeast New Brunswick. The project is well under way with objectives of promoting hemp farming and attendant year-round jobs.

A certified professional agronomist, Joan Parker-Duivenvoorden, has been hired to manage the project. She has over 15 years of experience with the Nova Scotia Department of Agriculture and with the New Brunswick Soil and Crop Improvement Association, which will prove invaluable as the project expands to encompass and employ over 50 farmers.

Planting has been completed on the first 77 acres, and the remaining 48 acres will be seeded soon. Drying equipment is being evaluated to process the hemp after harvest, and management is already in discussions with several potential processing partners for extraction of cannabinoids. Once all the licenses have been acquired for importing and manufacturing finished CBD products, the New Brunswick site could easily serve as a distribution center for MCOA’s hempSMART™ subsidiary.

In another joint venture with Global Hemp Group, MCOA is also developing Covered Bridge Acres, a high-yielding CBD hemp cultivation project in Oregon. Operations at the farm are well under way. The project will utilize both traditional outdoor cultivation and what will be over 19,296 square feet of greenhouses.

“Our evolving project in Scio, Oregon, highlights the quality of the team in place as they continue to lean on their many years of experience cultivating hemp. Activities such as these will help to secure the raw oil that we will need for our hempSMART brand of CBD infused products,” stated Donald Steinberg, MCOA’s CEO.

The Takeaway

With rapidly expanding retail distribution and burgeoning, diversified hemp cultivation programs underway, MCOA is fast approaching the vertical integration that typically impacts bottom lines and drives shareholder value.

Other companies already operating in the CBD space include:

Isodiol International (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) grows and harvests hemp on an industrial scale and then processes it to extract cannabidiol (CBD) for worldwide distribution. The company pioneered the commercialization of 99 percent-plus pure, pharmaceutical-grade cannabinoids, micro-encapsulations and nanotechnology for consumable and topical skin care products.

CV Sciences (OTC: CVSI) operates in two business segments. The company’s drug development division develops and commercializes novel therapeutics utilizing synthetic CBD. Its consumer product division manufactures, markets and sells plant-based CBD products to a range of market sectors.

Medical Marijuana (OTC: MJNA) develops, distributes and sells hemp oil that contains naturally occurring cannabinoids, including CBD, and other products containing CBD oil. The company sells its hemp-derived CBD products through its distribution subsidiaries. The company was among the first to bring hemp-based CBD oil products to market in the United States.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) out-licenses its patented delivery technology, which lowers dosing of lipophilic active molecules and enhances their effectiveness. The company’s technology increases intestinal absorption rates, speeds delivery to the bloodstream, and masks tastes for orally administered bioactive molecules including cannabinoids, vitamins, NSAIDs, nicotine and other molecules.

Together, MCOA and these companies weave a tapestry of industry, innovation and intuitive concern for the communities they serve with nature-based hemp products that appear to be once again losing the stigma that has come from being marijuana’s staider sibling.

For more information on Marijuana Company of America, visit Marijuana Company of America, Inc. (OTC: MCOA)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.